GlassScriptPhysician profile
Natee Poopat
NPI 1760492821
$5,556.72
in general payments reported to CMS, 2019-2025
20 companies · $945 in 2025
The $945 reported for 2025 was more than what 80% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
See the full distribution for Otolaryngology/Facial Plastic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $1,879 · 2021: $475 · 2022: $629 · 2023: $698 · 2024: $383 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,475.37 | 2020 | |
| Genzyme Corporation | $1,273.80 | 2019-2025 | |
| Intersect Ent, INC. | $739.50 | 2019-2021 | |
| Optinose US, INC. | $523.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $394.27 | 2022-2025 | Nucala |
| Aerin Medical INC. | $321.95 | 2022-2025 | |
| Inspire Medical Systems, INC. | $295.96 | 2024-2025 | Inspire |
| Acclarent, INC | $132.58 | 2019-2023 | Trudi Nav Cable |
| Smith+Nephew, INC. | $119.18 | 2024-2025 | Tula |
| Regeneron Healthcare Solutions, INC. | $84.58 | 2022-2025 | Dupixent |
| Medtronic, INC. | $60.56 | 2021-2023 | Nuvent |
| Stryker Corporation | $43.24 | 2019 | |
| Phadia US INC. | $18.84 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $16.21 | 2025 | Tezspire |
| Checkpoint Surgical, INC | $15.56 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.49 | 2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $13.95 | 2021 | |
| Henry Schein, INC. | $13.13 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natee Poopat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.